follow-up treatment News
-
U.S. Food and Drug Administration Clears UVision360, Inc. Novel LUMINELLE® 360° Bx (Biopsy) Sheath
UVision360, Inc., an innovative medical device company, announces today that the U.S. Food and Drug Administration (FDA) has approved the patented LUMINELLE 360° Bx (Biopsy) Sheath which expands the capability of the LUMINELLE® DTx System. The LUMINELLE 360° Bx sheath, combined with the LUMINELLE DTx System, is the first and only integrated directed biopsy device not requiring ...
By LUMINELLE
-
Kadimastem Announces the Approval of a 4M NIS ($1.29M) Budget from the Israel Innovation Authority
NESS ZIONA, ISRAEL, December 12, 2021 – Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a potential cure for diabetes, has received a grant of NIS 1.6 million ($500K), 40% of the approved budget of NIS 4 million ($1.29M) from the Israel Innovation Authority (IIA).This brings the total amount of financing raised by Kadimastem in 2021 to ...
-
Surgivisio launches pediatric app
Surgivisio today announced the launch of its pediatric application for spine surgery. The French company, which markets the only unified surgical platform combining 2D fluoroscopy, 3D imaging and real-time navigation, now offers its customers a pediatric mode with an additional X-ray optimization for dose reduction. "The development of a pediatric mode that would enable us to reduce the x-ray ...
-
REDUCE FMR Study Shows Cardiac Dimensions’ Carillon System Significantly Improves Mitral Regurgitation and Slows Worsening of Heart Failure
Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatments for functional mitral regurgitation (FMR) in patients with heart failure (HF), today announced the publication of the REDUCE FMR clinical study of its Carillon Mitral Contour System®. The Carillon System is a right heart transcatheter mitral valve repair (TMVr) device designed to treat the primary ...
-
Lyra Therapeutics Presents New Positive Phase 2 LANTERN 6-Month Follow-Up and LYR-210 Pharmacokinetic Data, and LANTERN Manuscript Wins Award at the 67th Annual Meeting of the American Rhinologic Society
LYR-210 pharmacokinetics indicate a constant and steady daily dose of Mometasone Furoate is delivered to patients LANTERN study manuscript wins ARS Annual Meeting 2021 Clinical Science Maurice Cottle Award Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of ...
-
Fractyl Health Publishes Two-Year Durability Data After a Single Revita DMR Therapeutic Procedure in Patients with Type 2 Diabetes
REVITA-1 was an open-label cohort study evaluating Revita® in patients with type 2 diabetes on oral anti-diabetic agents but not yet on insulin This is the first publication showing two-year durability of improvements in blood glucose, weight, and broader metabolic parameters with no device- or procedure-related adverse events in long-term follow-up after a single Revita procedure ...
-
DEFYMED at SFD congress in Nice (France)
Several people of the team (Severine, Karine and Manuel) are really happy to participate to the annual congress of the French society of diabetes (SFD) which will take place in Nice (South of France) from March 22nd to 25th. The team will be in the start-up booth E02 to present our latest news but also a unique chance for you to take in hands our ExOlin® device which is the latest innovation ...
By Defymed
-
ABK Biomedical Announces Enrollment Initiation of First-in-Human Clinical Study with Eye90 microspheres™ for treatment of liver tumors
ABK Biomedical, Inc., an innovative, clinical stage medical device company dedicated to the research, development and commercialization of advanced embolic therapies, announced the approval and initiation of a First-in-Human study with Eye90 microspheres™, a Y90 radioembolization device, in collaboration with Auckland Hospital Research Unit, New Zealand. The prospective, single-center, ...
-
Maia connected care is born, the telemedicine solution developed by ab medica
20 years of experience for a platform already tested, effective, fully integrable with the hospital flow and in continuous evolution. Ab medica starts from the many years of monitoring, developing a Class IIA Medical Device, compliant with the GDPR regulation and easily integrated with public and private information systems. Maia connected care is a modular platform that allows ...
-
ABK Biomedical Announces First Patient Treated in First-in-Human Clinical Study with Eye90 microspheres™ for treatment of liver tumors
ABK Biomedical, Inc., an innovative, clinical-stage medical device company dedicated to the research, development and commercialization of advanced imageable embolic therapies, announced the first patient treated in ABK’s First-in-Human study with Eye90 microspheres™, a Y90 radioembolization device for the treatment of liver cancers. This study is being conducted in collaboration ...
-
Alcyone Lifesciences Completes Spin-Off of Hydrocephalus Business, Anuncia
Alcyone Lifesciences, Inc., a privately-held company focused on transforming disease modifying therapies for central nervous system (CNS) disorders today announced the separation and spin-off of its Hydrocephalus business. The new company, known as Anuncia, Inc., is an independent company focused on better treatment of Hydrocephalus and cerebrospinal fluid dysfunctions. The separation and ...
-
First-in-Human Use of ReFlow for Treatment of Hydrocephalus
Anuncia, Inc., a privately-held company focused on better treatment of hydrocephalus and cerebrospinal fluid dysfunctions, announced, today, the successful first-in-human implantation of its Alivio ReFlow™ Ventricular System for treatment of hydrocephalus at Boston Children’s Hospital. This announcement comes on the heels of receiving the EU CE Mark and US FDA Clearance of Alivio ...
-
Molecular Matrix, Inc. Forms Strategic Alliance with Philosys Healthcare
On August 7, 2019, Molecular Matrix, Inc. (MMI) announced the signing of a Memorandum of Understanding (MOU) with Philosys Healthcare Co., Ltd., a biomedical distribution and manufacturing company based in Seongnam, South Korea. MMI is a biotechnology company that began as a startup at UC Davis, and after more than 10 years of research and development has created a scaffold for bone tissue ...
-
Revacept protects during carotid artery surgery
Good news from vascular medicine: the innovative drug Revacept can protect people with narrowed carotid arteries from both further strokes and dangerous bleeding. Thanks to this completely new dual efficacy, Revacept is ideal for preventing complications after stroke prevention surgery on narrowed carotid arteries. This is the result of an international study conducted according to the highest ...
-
Anuncia Medical, Inc., receives FDA clearance for the ReFlow System Mini for the treatment of patients with hydrocephalus
Anuncia Medical, Inc., announced that the U.S. Food and Drug Administration (FDA) cleared the ReFlow® System Mini for the treatment of patients with hydrocephalus and other cerebrospinal fluid (CSF) disorders that require shunting. Anuncia Medical announced FDA clearance of ReFlow® System Mini for the treatment of cerebrospinal fluid (CSF) disorders. The FDA 510(k) clearance allows ...
-
AngioDynamics Completes Patient Enrollment in APEX-AV Study Assessing AlphaVac F1885 System in Treatment of Pulmonary Embolism
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced the completion of patient enrollment in the Acute Pulmonary Embolism Extraction Trial with the AlphaVac System (APEX-AV). APEX-AV is a ...
-
Nucleix Presents Clinical Data at EAU21 Virtual Congress Which Demonstrates Promising Advances in the Care of Bladder Cancer Patients
SAN DIEGO & REHOVOT, ISRAEL--(BUSINESS WIRE)--Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, today announced data from two abstracts featuring its Bladder EpiCheck® test at the 36th Annual European Association of Urology (EAU) Virtual Congress. The first abstract titled, “Real world evidence of alternating cystoscopy/cytology ...
By Nucleix Ltd.
-
QIAGEN HPV DNA test donation to expand access to cervical cancer screening for women in rural India
QIAGEN today announced a key allocation from the company"s "one million test" donation program to increase access to HPV screening for cervical cancer prevention among women in low-resource regions of the world. Approximately 26,000 human papillomavirus (HPV) tests will go to the Nargis Dutt Memorial Cancer Hospital for cervical cancer screening, the company said at the Women Deliver global ...
-
Interim results of the Expander-1 Clinical Study
Medeon Biodesign, Inc. (TPEx: 6499), a Taiwan publicly traded medical device company, is pleased to announce positive interim results of the EXPANDER-1 Clinical Study for its flagship product the XFLO™ Expander System, an innovative, minimally invasive Benign Prostatic Hyperplasia (BPH) treatment solution. XFLO offers a reversible and office-based treatment option for patients who are ...
-
Ferring Presents Complete Data across Five RBX2660 Trials Demonstrating Consistent and Durable Efficacy in Recurrent C. difficile Infection, as Well as Multiple Analyses Demonstrating Positive Shifts in Microbiome Properties
Data from award-winning presentation at IDWeek 2021 represents the first time Ferring is showcasing the RBX2660 clinical development program as a whole, comprising the largest, most robust program ever conducted in the field of microbiome-based therapeutics for recurrent C. difficile infection (rCDI) Only gut microbiome research program with five clinical studies demonstrating consistent ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you